BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun DW, An L, Wei F, Mu L, Shi XJ, Wang CL, Zhao ZW, Li TF, Lv GY. Prognostic significance of parameters from pretreatment (18)F-FDG PET in hepatocellular carcinoma: a meta-analysis. Abdom Radiol (NY). 2016;41:33-41. [PMID: 26830609 DOI: 10.1007/s00261-015-0603-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Bastiaannet R, Lodge MA, de Jong HW, Lam MG. The Unique Role of Fluorodeoxyglucose-PET in Radioembolization. PET Clinics 2019;14:447-57. [DOI: 10.1016/j.cpet.2019.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kim JM, Kwon CHD, Joh J, Yoo H, Kim K, Sinn DH, Choi G, Lee JH. Nomograms in Hepatectomy Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. J Gastrointest Surg 2019;23:1559-67. [DOI: 10.1007/s11605-018-04074-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
3 Schobert I, Chapiro J, Pucar D, Saperstein L, Savic LJ. Fluorodeoxyglucose PET for Monitoring Response to Embolotherapy (Transarterial Chemoembolization) in Primary and Metastatic Liver Tumors. PET Clinics 2019;14:437-45. [DOI: 10.1016/j.cpet.2019.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Zhu D, Wang L, Zhang H, Chen J, Wang Y, Byanju S, Liao M. Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e7813. [PMID: 28816978 DOI: 10.1097/MD.0000000000007813] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.6] [Reference Citation Analysis]
5 Ozaki K, Harada K, Terayama N, Kosaka N, Kimura H, Gabata T. FDG-PET/CT imaging findings of hepatic tumors and tumor-like lesions based on molecular background. Jpn J Radiol 2020;38:697-718. [PMID: 32246350 DOI: 10.1007/s11604-020-00961-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Kornberg A, Schernhammer M, Friess H. 18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma. J Clin Transl Hepatol 2017;5:224-34. [PMID: 28936404 DOI: 10.14218/JCTH.2017.00014] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
7 Abouzied MM, Alhinti N, AlMuhaideb A, Al Sugair AS, Al Qahtani M. Extrahepatic metastases from hepatocellular carcinoma: multimodality image evaluation. Nucl Med Commun 2021;42:583-91. [PMID: 33625188 DOI: 10.1097/MNM.0000000000001380] [Reference Citation Analysis]
8 Tong AK, Tham WY, Too CW, Tai DW, Chow PK, Ng DC. Molecular Imaging and Therapy of Liver Tumors. Semin Nucl Med 2020;50:419-33. [PMID: 32768006 DOI: 10.1053/j.semnuclmed.2020.04.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Abuodeh Y, Naghavi AO, Ahmed KA, Venkat PS, Kim Y, Kis B, Choi J, Biebel B, Sweeney J, Anaya DA, Kim R, Malafa M, Frakes JM, Hoffe SE, El-Haddad G. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization. World J Gastroenterol 2016; 22(47): 10406-10414 [PMID: 28058021 DOI: 10.3748/wjg.v22.i47.10406] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
10 Levy CS, Costa FGB, Faria DP, Stefano JT, Cogliati B, Oliveira CP. 18F-FDG PET/CT as an assessment tool of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease development in experimental model.Arq Gastroenterol. 2019;56:45-50. [PMID: 31141073 DOI: 10.1590/S0004-2803.201900000-02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Howard BA, Wong TZ. 18F-FDG-PET/CT Imaging for Gastrointestinal Malignancies. Radiol Clin North Am 2021;59:737-53. [PMID: 34392916 DOI: 10.1016/j.rcl.2021.06.001] [Reference Citation Analysis]
12 Kim JM, Kwon CHD, Joh JW, Sinn DH, Choi GS, Paik SW. Prognosis of preoperative positron emission tomography uptake in hepatectomy patients. Ann Surg Treat Res. 2018;94:183-189. [PMID: 29629352 DOI: 10.4174/astr.2018.94.4.183] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
13 Jreige M, Mitsakis P, Van Der Gucht A, Pomoni A, Silva-Monteiro M, Gnesin S, Boubaker A, Nicod-Lalonde M, Duran R, Prior JO, Denys A, Schaefer N. 18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2017;44:1215-1222. [PMID: 28233086 DOI: 10.1007/s00259-017-3653-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
14 Lim CH, Moon SH, Cho YS, Choi JY, Lee K, Hyun SH. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with combined hepatocellular-cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2019;46:1705-12. [DOI: 10.1007/s00259-019-04327-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
15 Yoneda N, Matsui O, Kobayashi S, Kitao A, Kozaka K, Inoue D, Yoshida K, Minami T, Koda W, Gabata T. Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma. Jpn J Radiol. 2019;37:191-208. [PMID: 30712167 DOI: 10.1007/s11604-019-00817-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]